{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:04:55Z","timestamp":1774789495921,"version":"3.50.1"},"reference-count":40,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novartis Pharmaceuticals UK Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2022.2078103","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:02:22Z","timestamp":1652698942000},"page":"669-678","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-5850","authenticated-orcid":false,"given":"S.","family":"Montgomery","sequence":"first","affiliation":[{"name":"Costello Medical Consulting Ltd, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6958-840X","authenticated-orcid":false,"given":"F.","family":"Woodhouse","sequence":"additional","affiliation":[{"name":"Costello Medical Consulting Ltd, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7407-4059","authenticated-orcid":false,"given":"U.","family":"Vudumula","sequence":"additional","affiliation":[{"name":"Novartis Ireland Limited, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Gudala","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Private Limited, Hyderabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2393-8977","authenticated-orcid":false,"given":"M.","family":"Duddy","sequence":"additional","affiliation":[{"name":"Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kroes","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Ltd, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2006.11.015"},{"key":"e_1_3_5_4_1","unstructured":"Multiple Sclerosis Trust \u2013 Prevalence and Incidence of Multiple Sclerosis [cited 2021 June 08]. Available from: https:\/\/mstrust.org.uk\/a-z\/prevalence-and-incidence-multiple-sclerosis."},{"key":"e_1_3_5_5_1","unstructured":"MS Society. Types of MS. [cited 2021 June 03]. Available from: https:\/\/www.mssociety.org.uk\/about-ms\/types-of-ms\/relapsing-remitting-ms."},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458507084264"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09489-5"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103174"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.474"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00581-x"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.4128"},{"key":"e_1_3_5_14_1","first-page":"328","article-title":"Siponimod slows physical disability progression and decline in cognitive processing speed in SPMS patients with active disease: a post hoc analysis of the EXPAND study","volume":"27","author":"Gold R","year":"2020","unstructured":"Gold R, Kappos L, Benedict R, et\u00a0al. Siponimod slows physical disability progression and decline in cognitive processing speed in SPMS patients with active disease: a post hoc analysis of the EXPAND study. Eur J Neurol. 2020;27:328\u2013329.","journal-title":"Eur J Neurol"},{"key":"e_1_3_5_15_1","first-page":"P750","article-title":"Efficacy of siponimod in secondary progressive multiple sclerosis patients with active disease: the EXPAND study subgroup analysis","volume":"279110","author":"Gold R","year":"2019","unstructured":"Gold R, Kappos L, Bar-Or A, et\u00a0al. Efficacy of siponimod in secondary progressive multiple sclerosis patients with active disease: the EXPAND study subgroup analysis. ECTRIMS Online Library. 2019;279110:P750.","journal-title":"ECTRIMS Online Library"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011275"},{"key":"e_1_3_5_17_1","unstructured":"National Institute for Health and Care Excellence. Siponimod for treating secondary progressive multiple sclerosis (TA656). 2020. [cited 2021 June 03]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta656."},{"key":"e_1_3_5_18_1","unstructured":"Scottish Medicines Consortium. Siponimod (Mayzent\u00ae) 2020. [cited 2021 July 05]. Available from: https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/siponimod-mayzent-full-smc2265\/."},{"key":"e_1_3_5_19_1","unstructured":"Transition to secondary progressive multiple sclerosis: When is SPMS identified in the UK and what are the consequences for patients and the National Health Service? Presented at the MS Trust Conference 2019 [cited 2021 July 05]. Available from: https:\/\/mstrust.org.uk\/sites\/default\/files\/ms_conference_posters_2019_Caseby_FINAL.pdf."},{"key":"e_1_3_5_20_1","unstructured":"National Institute for Health and Care Excellence. Natalizumab for the treatment of adults with highly active relapsing\u2013remitting multiple sclerosis (TA127) 2007. [cited 2021 June 08]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta127."},{"key":"e_1_3_5_21_1","unstructured":"National Institute for Health and Care Excellence. Fingolimod for the treatment of highly active relapsing\u2013remitting multiple sclerosis (TA254) 2012. [cited 2021 June 08]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta254."},{"key":"e_1_3_5_22_1","unstructured":"National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320) 2014. [cited 2021 June 08]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta320."},{"key":"e_1_3_5_23_1","unstructured":"National Institute for Health and Care Excellence. Teriflunomide for treating relapsing\u2013remitting multiple sclerosis (TA303) 2014. [cited 2021 June 08]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta303."},{"key":"e_1_3_5_24_1","unstructured":"National Institute for Health and Care Excellence. Ocrelizumab for treating relapsing\u2013remitting multiple sclerosis (TA533) 2018. [cited 2021 June 08]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta533."},{"key":"e_1_3_5_25_1","unstructured":"European Medicines Agency. Mayzent: EPAR \u2013 Public assessment report. 2020. [cited 2021 November 02]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/mayzent-epar-public-assessment-report_en.pdf."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01023-8"},{"key":"e_1_3_5_27_1","unstructured":"Treatment Algorithm for Multiple Sclerosis Disease-Modifying Therapies (NHS England Reference: 170079ALG) 2019 [cited 2021 July 15]. Available from: https:\/\/www.england.nhs.uk\/commissioning\/wp-content\/uploads\/sites\/12\/2019\/03\/Treatment-Algorithm-for-Multiple-Sclerosis-Disease-Modifying-Therapies-08-03-2019-1.pdf."},{"issue":"2","key":"e_1_3_5_28_1","first-page":"101","article-title":"Long-term survival experience of patients with multiple sclerosis","volume":"29","author":"Pokorski RJ.","year":"1997","unstructured":"Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med. 1997;29(2):101\u2013106.","journal-title":"J Insur Med"},{"key":"e_1_3_5_29_1","unstructured":"Office for National Statistics. National Life Tables England. 2017\u20132019. 2021 [cited 2021 May 21]. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesenglandreferencetables."},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30069-3"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012354"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0122"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1982.tb03084.x"},{"key":"e_1_3_5_34_1","volume-title":"Personal social services research unit","author":"Curtis L","year":"2020","unstructured":"Curtis L, Burns A. Personal social services research unit. Canterbury: University of Kent; 2020."},{"key":"e_1_3_5_35_1","unstructured":"NHS National Tariff 2019\u20132020 London: NHS; 2021 [cited 2021 July 08]. Available from: https:\/\/www.england.nhs.uk\/national-cost-collection\/."},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00192.x"},{"key":"e_1_3_5_37_1","unstructured":"National Institute for Health and Care Excellence. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527) 2018. [cited 2021 June 11]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta527."},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00144.x"},{"key":"e_1_3_5_39_1","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. 2013. [cited 2021 June 10]. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword."},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322326"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1719393"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2078103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:24:20Z","timestamp":1729164260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2078103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2078103"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2078103","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}